ArticleJournal of global health2023
Global epidemiology of early-onset liver cancer attributable to specific aetiologies and risk factors from 2010 to 2019.
Article in Journal of global health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Exposure to Per- and Polyfluoroalkyl Substances and Liver Cancer: A Systematic Review of Animal and Epidemiological Studies.Environmental science & technology · 2026Pooled it
- Global, Regional, and National Burden of Liver Cancer from 1990 to 2021 and Projections to 2050: A Global Burden of Disease Study 2021.Gut and liver · 2026Article
- Early-Onset Digestive System Cancers: Risk Factors and Clinicopathological and Molecular Features Across Organ Sites.Cancer science · 2026Review
- Machine learning-based early survival prediction in early-onset hepatocellular carcinoma: a SEER-based multi-model comparative study.Translational cancer research · 2026Article
- Global trends in early-onset liver cancer incidence and projections to 2050 based on the global burden of disease study 2021.Discover oncology · 2026Article
- Disease burden and prediction of liver cancer attributable to metabolic risks in five East Asian countries from 1990 to 2023.PloS one · 2026Article
- Global, regional, and national burden of NAFLD in adults aged 20-49 years (1990-2021): a comprehensive analysis of trends, decomposition, and health inequality.BMC gastroenterology · 2025Article
- Global Epidemiology of Smoking and Liver Cancer from 1990 to 2021.Diseases (Basel, Switzerland) · 2025Article
- The microbiome-cancer axis as a hidden contributor to early-onset tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- Article
- Global Epidemiology of Early-Onset Digestive System Malignancy: A Systematic Analysis for the Global Burden of Disease Study 2021.Journal of gastroenterology and hepatology · 2025Article
- Are More Young, Western Patients Also Developing Hepatocellular Carcinoma?Annals of surgical oncology · 2025Article
- Global, regional and national burden of liver cancer 1990-2021: a systematic analysis of the global burden of disease study 2021.BMC public health · 2025Article
- Young Adults and Alcohol-Associated Liver Cancer: Incidence and Death from 2000 to 2021.Cancers · 2025Article
- Global, regional, and national burden of liver cancer in adolescents and young adults from 1990 to 2021: an analysis of the global burden of disease study 2021 and forecast to 2040.Frontiers in public health · 2025Article
- Global, regional and country burden of high BMI-related liver cancer among individuals aged above 70: trends from 1990 to 2021 and projections to 2044.Frontiers in public health · 2025Article
- The health burden of disease attributable to low calcium intake: a comprehensive analysis of trends and socioeconomic impacts from 1990 to 2021.Frontiers in nutrition · 2025Article
- Epidemiology of liver cancer in Kazakhstan: data from the Unified National Electronic Health System, 2014-2023.PloS one · 2025Article
- Global trends and forecasts of nonalcoholic steatohepatitis causing liver cancer incidence and deaths.Frontiers in oncology · 2025Article
- Liver Cancer Etiology: Old Issues and New Perspectives.Current oncology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Considering its emergence as a public health concern worldwide, with potential spatial-temporal heterogeneities, we aimed to determine the global burden of early-onset liver cancer attributable to aetiologies and concomitant risk factors. Methods: We used data from the Global Burden of Diseases Study 2019 to determine age-standardised disability-adjusted life-year (DALY) rates for early-onset liver cancer by aetiologies and the population DALYs attributable to concomitant risk factors between 2010 and 2019. We also calculated estimated annual percentage changes (EAPCs) to measure temporal trends. Results: There were 2.9 million DALYs related to early-onset liver cancer globally in 2019. East Asia contributed over half of DALYs, which increased annually by 1.23% (95% confidence interval (CI) = 0.71, 1.76) between 2010 and 2019. Non-alcoholic steatohepatitis was the only growing aetiology. The proportion of DALYs attributed to metabolic risks increased by 22.50% (95% CI = 14.33, 38.13), while behavioral risks remained stable. Obesity surpassed smoking as the most prevalent nondeterministic aetiological risk factor from 2010 to 2019, while the population DALY attributable to hepatitis B combined with obesity increased by 29.93% (95% CI = 8.49, 60.77) in the same period, making it the principal joint contributor. Conclusions: Early-onset liver cancer poses considerable disability and continues to increase in many regions, especially in East Asia. Metabolic risk factors, particularly when hepatitis B and obesity coexist, are the fastest-growing contributors to this type of cancer. More targeted interventions are imperative to curb the growing burden of early-onset liver cancer due to metabolic risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.